Patient Summit USA 2016

eyeforpharma 10 - 11 October 2016, Sonesta Philadelphia, USA.
The 13th annual Patient Summit USA 2016 is where patient-driven partnerships with stakeholders actually happen. This is not just a talking shop - be one of 300+ senior pharma executives, regulatory authorities, providers, payers, advocates and patients who plan to deliver sustainable solutions to the patient community.

Patient Centricity ...so what?

  • Streamline cultural change by setting a universal framework for patient centricity
  • Prove ROI-driven patient initiatives and get internal buy-in
  • Hear directly from patients and caregivers and mend their disconnect with the industry
  • Overcome roadblocks to advocacy and adherence with an enhanced focus on access programs
  • Navigate a complex regulatory environment while still promoting your patient initiatives

Turn profit-patient into patient-profit
Transforming your profit-patient model into a patient-profit system is one of the biggest shake-ups in pharma's history.

Many major brands are already in the process of creating and developing a new patient-centric approach, and introducing measures to reward staff against patient-oriented metrics.

What was once an 'if?' has become a 'when and how?'. But changing an engrained mind-set requires a collaborative effort; the more companies that encourage–and in some cases enforce–patient-centricity, the more widespread the buy-in will be.

'Profit' is still a valid talking point - it hasn't become a dirty word. What has changed is that it is now being seen as a natural by-product of putting patients first.

Now that patients are being almost universally regarded as pivotal to the sustained growth of pharma, the question turns back to: how will an inverted model still provide profit for pharma and key stakeholders?

The conference aims to help pharma stakeholders share views, and examine ways to put patients at the centre of evolving pharma business models, without damaging profits. Putting patients first needs to be attractive on both the humanistic and fiscal levels in order for patient centricity to thrive.

World Pharma News readers can benefit from an exclusive discount code, save €200 using World Pharma News unique code WorldPharma200

For further information, please visit:
http://www.eyeforpharma.com/patientusa/

About eyeforpharma
Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry's health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the center.

Most Popular Now

Regorafenib to be tested in brain cancer patients …

Bayer announced that the regorafenib arm of the platform trial "GBM AGILE" (Glioblastoma Adaptive Global Innovative Learning Environment) opened for enrollment in the US ...

Sanofi and Google to develop new healthcare Innova…

Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping i...

Bristol-Myers Squibb provides update on pending me…

Bristol-Myers Squibb Company (NYSE: BMY) today provided an update on the approval process and timeline for the Company’s pending merger with Celgene Corporation (NASDAQ: ...

Japan becomes the first country to approve Roche's…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Rozlytrek® (entrectinib) for the treatment of a...

Breztri Aerosphere (PT010) approved in Japan for p…

AstraZeneca announced that Breztri Aerosphere (budesonide/glycopyrronium/ formoterol fumarate), formerly PT010, has been approved in Japan as a triple-combination therapy...

FDA approves Amgen and Allergan's KANJINTITM (tras…

Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTITM (trastuzumab-anns) for all approved ind...

Vitamin D may not help your heart

While previous research has suggested a link between low levels of vitamin D in the blood and an increased risk of cardiovascular disease, a new Michigan State University...

Human-on-a-chip model tests cancer drug efficacy a…

A reconfigurable "body-on-a-chip" model could transform drug development by simultaneously measuring compound efficacy and toxicity, for both target cells and other organ...

Pathogen engineered to self-destruct underlies can…

A team of investigators has developed a cancer vaccine technology using live, attenuated pathogens as vectors. A feature of the vaccine causes these bacteria to self-dest...

Artificial DNA can control release of active ingre…

A drug with three active ingredients that are released in sequence at specific times: Thanks to the work of a team at the Technical University of Munich (TUM), what was o...

How gastric stem cells fight bacteria

Stem cells are not only key players in tissue regeneration, they are also capable of taking direct action against bacteria. This is the finding of a study conducted by re...

Researchers identify enzyme that suppresses immune…

Immunotherapies have transformed cancer care, but their successes have been limited for reasons that are both complex and perplexing. In breast cancer especially, only a ...